Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02953678 · FLOW

Participant flow

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) · Source last updated 2021-11-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Participants began oral administration of ruxolitinib at 5 mg twice a day (BID); if stable after the first 3 days of treatment, the dose may be increased to 10 mg BID. Participants did receive prednisone 2.5 mg/kg per day orally (PO) or methylprednisolone 2.0 mg/kg per day IV.
    id
    FG000
    title
    Ruxolitinib in Combination With Corticosteroids
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        20
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        7
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        23
      type
      Physician Decision
    4. reasons
      1. group Id
        FG000
        num Subjects
        7
      type
      Progressive Disease of GVHD
    5. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Relapse of Underlying Malignancy
    6. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Withdrawal by participant
    7. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Includes 2 participants who discontinued ruxolitinib treatment because of clinical improvement
    8. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Participants were transferred to commercial product.
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        71
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        71
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
This study was conducted at 26 study centers in the United States.
Complete source fields
groups
  1. description
    Participants began oral administration of ruxolitinib at 5 mg twice a day (BID); if stable after the first 3 days of treatment, the dose may be increased to 10 mg BID. Participants did receive prednisone 2.5 mg/kg per day orally (PO) or methylprednisolone 2.0 mg/kg per day IV.
    id
    FG000
    title
    Ruxolitinib in Combination With Corticosteroids
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        20
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        7
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        23
      type
      Physician Decision
    4. reasons
      1. group Id
        FG000
        num Subjects
        7
      type
      Progressive Disease of GVHD
    5. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Relapse of Underlying Malignancy
    6. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Withdrawal by participant
    7. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Includes 2 participants who discontinued ruxolitinib treatment because of clinical improvement
    8. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Participants were transferred to commercial product.
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        71
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        71
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
This study was conducted at 26 study centers in the United States.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice